The supposedly undruggable protein is finally druggable
For decades, pancreatic cancer has occupied a grim corner of medicine where genetics seemed to foreclose hope — a single mutated gene, KRAS, driving the disease in nine of ten patients while resisting every molecular intervention scientists could devise. Now, in the late spring of 2026, a drug called daraxonrasib has emerged from a Phase 3 trial of 500 patients with results that nearly double median survival, suggesting that what was long called undruggable may finally be within reach. The announcement by Revolution Medicines marks not merely a clinical milestone but a conceptual one — proof that the architecture of cancer's most entrenched defenses can, with enough ingenuity, be circumvented.
- Pancreatic cancer has carried one of medicine's worst prognoses for generations, with metastatic patients facing a median survival of under seven months and a five-year survival rate hovering near three percent.
- The KRAS mutation powering over 90% of cases was considered structurally impossible to drug — its smooth protein surface offered no foothold for conventional therapies, leaving oncologists reliant on blunt chemotherapy.
- Daraxonrasib sidesteps the problem entirely by hijacking a helper molecule called cyclophilin A, which then latches onto and silences the mutant KRAS signal — a workaround that proved potent enough to cut death risk by 60% in trial.
- Side effects were widespread — rashes in 86% of patients, mouth sores, and gastrointestinal distress — yet patients tolerated the drug better than chemotherapy and reported meaningfully improved quality of life.
- Revolution Medicines is moving toward FDA submission, with expedited review possible given the magnitude of benefit, and researchers are already eyeing combination therapies to stay ahead of tumor resistance.
Pancreatic cancer has long functioned as a kind of biological inevitability. The metastatic form — cancer already spread beyond the pancreas — kills with quiet efficiency, offering no reliable screening, no early symptoms, and by the time jaundice or abdominal pain drives a patient to seek help, the disease has usually already claimed other organs. Chemotherapy has been the primary weapon, powerful but imprecise, and pancreatic cancer cells have proven remarkably skilled at outlasting it.
The disease's lethality is rooted in genetics. More than 90 percent of cases are driven by mutations in the KRAS gene, which produces proteins that act as molecular switches governing cell growth. When KRAS mutates, the switch locks permanently open, flooding cells with signals to multiply without end. For decades, the protein was considered impossible to target — its surface too smooth, too featureless, to give any drug a grip.
That assumption has now been challenged in a meaningful way. On May 31, 2026, Revolution Medicines announced Phase 3 results for daraxonrasib, tested in 500 patients with metastatic pancreatic cancer who had already undergone prior treatment. Median survival climbed from 6.7 months to 13.2 months. The risk of death fell by 60 percent. The drug achieves this not by attacking KRAS directly but through a molecular detour — binding to a protein called cyclophilin A, which then latches onto the mutated KRAS and shuts down its cancer-driving signal. It is taken as a daily oral pill.
Side effects were common: rashes appeared in more than 86 percent of patients, mouth sores were widespread, and gastrointestinal symptoms were frequent. Yet patients on daraxonrasib were less likely to abandon treatment from severe toxicity than those on chemotherapy, and they reported less pain and better overall quality of life — a meaningful shift in the burden of care.
Regulatory submission to the FDA and international bodies is expected soon, with expedited review likely given the scale of benefit. Beyond this single drug, the trial carries a larger implication: by demonstrating that KRAS can be silenced, researchers have opened a conceptual door that had been closed for decades. Combination strategies to prevent resistance are already being contemplated, and a treatment landscape that had remained largely unchanged for a generation now appears ready to move.
Pancreatic cancer has long been a death sentence. Between 2015 and 2021, roughly 97 percent of patients diagnosed with the metastatic form—cancer that had already spread beyond the pancreas—were dead within five years. The disease kills so efficiently in part because it hides. There are no reliable screening tests. Early stages produce no symptoms worth noticing. By the time a patient feels jaundice yellowing their skin or experiences abdominal pain sharp enough to seek help, the cancer has usually already colonized other organs. Treatment has relied on chemotherapy, drugs potent enough to kill rapidly dividing cells but blunt enough to damage healthy tissue along the way, and pancreatic cancer cells have proven adept at developing resistance.
The reason pancreatic cancer is so lethal lies in its genetics. More than 90 percent of cases are driven by mutations in a single gene: KRAS. This gene produces proteins that function as molecular switches, toggling cell growth on and off. When KRAS mutates, the switch jams in the "on" position, and cancer cells receive an endless command to multiply. For decades, scientists considered KRAS untouchable. The protein's surface is smooth, almost featureless—lacking the molecular pockets where conventional drugs could grip and turn the switch off. It seemed impossible to drug.
That assumption is now cracking. On May 31, 2026, Revolution Medicines announced results from a Phase 3 clinical trial of a new drug called daraxonrasib, tested in 500 patients with metastatic pancreatic cancer who had already received prior treatment. The results were striking: median survival nearly doubled, climbing from 6.7 months to 13.2 months. The drug reduced the overall risk of death by 60 percent. Daraxonrasib works through an elegant workaround. Rather than attacking KRAS directly, it binds to a molecule called cyclophilin A—a protein that helps fold other proteins into their final three-dimensional shapes. This complex then latches onto the mutated KRAS protein and silences its cancer-driving signal. The drug is taken daily by mouth.
The side effects are real. More than 86 percent of patients developed a prominent skin rash. Many experienced stomatitis, the painful swelling and ulceration of mouth tissue. Diarrhea, nausea, and vomiting were common. Yet patients taking daraxonrasib were significantly less likely to abandon treatment due to severe toxicity compared to those on chemotherapy, and they reported better quality of life with reduced pain. The calculus had shifted: the drug's burden was tolerable in ways that traditional chemotherapy was not.
What happens next depends on regulatory machinery. Revolution Medicines will submit daraxonrasib to the Food and Drug Administration and other global regulatory bodies for formal approval. Because advanced pancreatic cancer is so difficult to treat, breakthrough therapies showing this magnitude of survival benefit often receive expedited review. If approval comes through, the drug could reach clinics within months. The implications extend beyond this single medication. By proving that the supposedly undruggable KRAS mutation can be targeted, researchers have opened a door. Future trials will likely explore combining KRAS inhibitors with other drugs to prevent tumors from developing resistance. The landscape of pancreatic cancer treatment, static for decades, appears poised to shift.
Citações Notáveis
For decades, scientists considered KRAS to be undruggable because the protein's surface lacks the molecular pockets that standard drugs require to bind and turn the switch off— Oncology researcher and author
Patients taking daraxonrasib were far less likely to stop treatment due to severe side effects compared to chemotherapy, and they had improved quality of life with reduced pain— Clinical trial data
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take so long to crack KRAS? It's just a protein.
The protein's structure is the problem. It's smooth—no pockets for drugs to grip. Conventional medicines work like keys fitting into locks. KRAS has no lock.
So how does daraxonrasib get around that?
It doesn't attack KRAS directly. It recruits a helper protein called cyclophilin A, which binds to KRAS and shuts it down. It's indirect, but it works.
The survival numbers are impressive. But 13 months is still short.
It is. But it's double what these patients had before. And it's a foundation. Doctors will likely combine this with other drugs to keep resistance from developing.
The rash affects 86 percent of patients. That's almost everyone.
True. But patients tolerate it better than chemotherapy. They stay on the drug. They report less pain. The side effect profile is harsh but manageable in ways the old treatments weren't.
What's the timeline for patients to actually get this?
Regulatory review could take months. If the FDA grants expedited approval, it could be in clinics by late 2026 or early 2027. But that depends on how quickly the agency moves.
Does this change how doctors think about pancreatic cancer?
Fundamentally. For decades, the disease felt inevitable. Now there's a tool that works. It won't cure everyone, but it shifts the conversation from "manage the decline" to "target the mutation."